샘플 요청 목록

 카트 문의
시장보고서
상품코드
1787191

세계의 mRNA 치료제 위탁개발생산 시장

mRNA Therapeutics Contract Development & Manufacturing Organization
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 166 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 mRNA 치료제 위탁개발생산 시장 규모는 2030년까지 90억 달러에 달할 전망

세계의 mRNA 치료제 위탁개발생산 시장 규모는 2024년에 50억 달러로 추정되며, 2024-2030년의 분석 기간 동안에 CAGR 10.3%로 성장하여 2030년에는 90억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 감염증 적응은 CAGR 8.8%를 기록하며 분석 기간 종료시에는 50억 달러에 달할 것으로 예측됩니다. 대사·유전성 질환 부문의 성장률은 분석 기간 동안 CAGR 12.8%로 추정됩니다.

미국 시장은 13억 달러로 추정, 중국은 CAGR 9.5%로 성장 예측

미국의 mRNA 치료제 위탁개발생산 시장은 2024년에는 13억 달러에 달할 것으로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 14억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간 2024-2030년 CAGR은 9.5%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 8.9%와 8.5%로 예측됩니다. 유럽에서는 독일이 CAGR 8.3%로 성장할 것으로 예측됩니다.

mRNA 치료제 위탁개발생산 세계 시장 : 주요 동향 및 촉진요인 개요

mRNA 치료제 CDMO에 대한 수요가 증가하는 이유는 무엇일까?

mRNA 기반 의약품과 백신의 등장으로 mRNA 치료제 전문 개발 및 제조수탁기관(CDMO)에 대한 수요가 크게 증가하고 있습니다. 생명공학 기업 및 제약회사는 연구개발에 집중하고 있어 mRNA의 대규모 생산에 필요한 인프라를 갖추지 못한 기업이 많아 전문 CDMO에 대한 요구가 높아지고 있습니다. 이들 조직은 원료 조달, 시험관 내 전사(IVT), 정제, 지질나노입자(LNP) 제형화 등 필수적인 서비스를 제공합니다. 특히 COVID-19 팬데믹 상황에서 입증된 mRNA 치료제의 빠른 확장성은 전 세계 백신 및 의약품 공급을 보장하는 데 있어 CDMO의 중요성을 더욱 강조하고 있습니다. 또한, mRNA의 용도가 백신뿐만 아니라 맞춤의료, 암 면역치료, 희귀질환 치료로 확대되면서 제조의 복잡성이 높아져 전문 CDMO에 아웃소싱하는 것이 전략적으로 필요하게 되었습니다. 생명공학 산업이 혁신을 거듭하는 가운데 CDMO는 임상 개발 및 상업 생산의 격차를 해소하고 mRNA 치료제가 효율적이고 비용 효율적으로 시장에 출시될 수 있도록 보장하는 중요한 역할을 하고 있습니다.

어떤 혁신이 mRNA 치료제 제조를 변화시키고 있는가?

기술의 발전은 mRNA 치료제 생산의 효율성과 확장성을 크게 향상시켰고, 의약품 제조에서 CDMO의 역할을 강화했습니다. 가장 중요한 기술 혁신 중 하나는 자동화된 폐쇄 시스템 IVT 공정의 개발로 오염 위험을 줄이고 배치 일관성을 향상시켰으며, 이를 통해 오염 위험을 줄였습니다. 또한, 지질나노입자(LNP) 캡슐화 기술의 개선으로 mRNA의 안정성과 표적에 대한 전달이 개선되어 최적의 치료 효과를 얻을 수 있게 되었습니다. AI를 활용한 mRNA 서열 설계 최적화 및 예측 모델링을 통해 CDMO는 생산 파라미터를 개선하고 낭비를 줄이고 수율을 향상시킬 수 있게 되었습니다. 또한, 일회용 바이오프로세싱 시스템의 발전으로 CDMO는 비용과 교차 오염의 위험을 최소화하면서 유연성을 높일 수 있게 되었습니다. 연속 생산 및 실시간 품질 관리 시스템은 제조 워크플로우를 더욱 간소화하여 임상 및 상업적 규모의 제조에서 납기를 단축할 수 있습니다. mRNA 기반 치료법이 자가증폭 RNA(saRNA)와 순환 RNA(circRNA)로 진화하는 가운데, CDMO는 혁신적인 mRNA 플랫폼에 대한 수요 증가에 대응하기 위해 최첨단 제조기술에 투자하고 있습니다.

규제와 공급망 요인은 mRNA 치료제 CDMO 시장을 어떻게 형성하고 있는가?

규제 요건의 복잡성과 세계 공급망 역학이 mRNA에 특화된 CDMO의 경영 전략을 형성하고 있습니다. FDA 및 EMA와 같은 규제 기관은 mRNA 치료제에 대한 엄격한 가이드라인을 제정하고 있으며, CDMO는 GMP를 준수하는 시설을 유지하고 엄격한 품질 관리 프로토콜을 시행해야 합니다. 맞춤형 의료의 진화에 따라, 특히 맞춤형 제제를 필요로 하는 mRNA 기반 암 백신과 유전자 치료제의 경우, 규제 상황의 승인 경로가 더욱 복잡해지고 있습니다. 뉴클레오티드, 캡핑 시약, 지질을 포함한 필수 원료의 세계 공급망도 혼란에 직면하고 있으며, CDMO는 중단 없는 생산을 보장하기 위해 지역 제조 허브와 수직적 통합 전략에 투자해야 합니다. 또한, CDMO와 생명공학 기업과의 협력을 통해 공급망의 강인성을 강화하고, 새로운 헬스케어 과제에 신속하게 대응할 수 있게 되었습니다. 디지털 제조 플랫폼과 블록체인 기반 추적 시스템의 채택으로 추적성과 컴플라이언스가 더욱 향상되어 mRNA 기반 의약품 생산 및 유통의 투명성을 보장하고 있습니다.

mRNA 치료제 CDMO 시장의 주요 성장 촉진요인은?

mRNA 치료제 CDMO 시장의 성장은 mRNA 의약품 개발에 대한 투자 증가, 바이오의약품 파이프라인의 확장, 확장 가능한 제조 솔루션에 대한 수요 증가 등 여러 요인에 의해 이루어지고 있습니다. mRNA 기반 COVID-19 백신의 성공으로 차세대 mRNA 치료제에 대한 자금 조달이 가속화되고 있으며, 감염, 종양, 대사성 질환을 대상으로 한 임상시험이 급증하고 있습니다. 제약사들은 운영비용을 절감하고 시장 출시 기간을 단축하기 위해 CDMO에 mRNA 생산을 위탁하는 사례가 늘고 있습니다. 자가증폭 RNA, 원형 RNA 등 차세대 RNA 기술의 등장으로 CDMO의 전문 역량에 대한 수요는 더욱 증가하고 있습니다. 또한, 모듈식 및 일회용 바이오프로세싱 시스템의 채택이 증가함에 따라 CDMO는 유연하고 비용 효율적인 제조 솔루션을 제공할 수 있게 되었습니다. 정부와 생명공학 기업들이 팬데믹 대비와 맞춤형 의료를 우선시하는 가운데, mRNA 치료제 CDMO의 역할이 확대되고 혁신적인 mRNA 기반 치료제가 효율적이고 대규모로 세계 시장에 도달할 것으로 기대됩니다.

부문

적응증(감염증 적응, 대사·유전질환, 심혈관·뇌혈관질환), 용도(바이러스 백신, 단백질 대체요법, 암 면역치료), 최종 용도(바이오테크놀러지 기업, 정부·학술연구기관, 제약 기업)

조사 대상 기업 사례

  • AGC Biologics
  • Aldevron
  • ARCALIS, Inc.
  • BioNTech SE
  • Catalent, Inc.
  • CordenPharma International
  • Curia Global, Inc.
  • FUJIFILM Diosynth Biotechnologies
  • Laboratorios Farmaceuticos Rovi, S.A.
  • Lonza Group
  • Merck KGaA
  • Moderna, Inc.
  • Rentschler Biopharma SE
  • Samsung Biologics
  • ST Pharm
  • Thermo Fisher Scientific
  • TriLink BioTechnologies
  • Vernal Biosciences
  • WuXi AppTec

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

일반적으로 진행되는 LLM 및 업계 특화형 SLM에 대한 쿼리에 의존하는 대신 우리는 세계 도메인 전문가가 엄선한 컨텐츠를 집약한 리포지토리를 구축했습니다. 여기에는 비디오 녹취록, 블로그, 검색 엔진을 이용한 조사, 방대한 기업 데이터, 제품 및 서비스 정보, 시장 데이터가 포함되어 있습니다.

관세 영향 계수

우리는 본사의 국가, 제조거점, 수출입(완제품과 OEM)에 따른 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

KSM 25.08.21

Global mRNA Therapeutics Contract Development & Manufacturing Organization Market to Reach US$9.0 Billion by 2030

The global market for mRNA Therapeutics Contract Development & Manufacturing Organization estimated at US$5.0 Billion in the year 2024, is expected to reach US$9.0 Billion by 2030, growing at a CAGR of 10.3% over the analysis period 2024-2030. Infectious Diseases Indication, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$5.0 Billion by the end of the analysis period. Growth in the Metabolic & Genetic Diseases Indication segment is estimated at 12.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 9.5% CAGR

The mRNA Therapeutics Contract Development & Manufacturing Organization market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 9.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.9% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global mRNA Therapeutics Contract Development & Manufacturing Organization Market - Key Trends & Drivers Summarized

Why Is the Demand for mRNA Therapeutics CDMOs Increasing?

The rise of mRNA-based drugs and vaccines has dramatically increased the demand for contract development and manufacturing organizations (CDMOs) specializing in mRNA therapeutics. As biotechnology and pharmaceutical companies focus on research and development, many lack the infrastructure required for large-scale mRNA production, driving the need for specialized CDMOs. These organizations provide essential services, including raw material sourcing, in vitro transcription (IVT), purification, and lipid nanoparticle (LNP) formulation. The rapid scalability of mRNA therapeutics, particularly demonstrated during the COVID-19 pandemic, has reinforced the importance of CDMOs in ensuring global vaccine and drug supply. Additionally, the expansion of mRNA applications beyond vaccines into personalized medicine, cancer immunotherapy, and rare disease treatments has increased the complexity of production, making outsourcing to expert CDMOs a strategic necessity. As the biotech industry continues to innovate, CDMOs have become crucial in bridging the gap between clinical development and commercial manufacturing, ensuring that mRNA therapeutics reach the market efficiently and cost-effectively.

What Innovations Are Transforming the Manufacturing of mRNA Therapeutics?

Technological advancements have significantly improved the efficiency and scalability of mRNA therapeutics manufacturing, enhancing the role of CDMOs in drug production. One of the most critical innovations is the development of automated and closed-system IVT processes, which reduce contamination risks and improve batch consistency. The refinement of lipid nanoparticle (LNP) encapsulation technology has also improved mRNA stability and targeted delivery, ensuring optimal therapeutic effects. AI-driven optimization of mRNA sequence design and predictive modeling have enabled CDMOs to refine production parameters, reducing waste and improving yield. Additionally, advancements in single-use bioprocessing systems have allowed CDMOs to enhance flexibility while minimizing costs and cross-contamination risks. Continuous manufacturing and real-time quality control systems have further streamlined production workflows, enabling faster turnaround times for clinical and commercial-scale manufacturing. As mRNA-based therapies evolve to include self-amplifying RNA (saRNA) and circular RNA (circRNA), CDMOs are investing in cutting-edge production techniques to meet the growing demand for innovative mRNA platforms.

How Are Regulatory and Supply Chain Factors Shaping the CDMO Market for mRNA Therapeutics?

The increasing complexity of regulatory requirements and global supply chain dynamics is shaping the operational strategies of mRNA-focused CDMOs. Regulatory agencies such as the FDA and EMA have established stringent guidelines for mRNA therapeutics, requiring CDMOs to maintain GMP-compliant facilities and implement rigorous quality control protocols. The evolving landscape of personalized medicine has further complicated regulatory approval pathways, particularly for mRNA-based cancer vaccines and gene therapies that require customized formulations. The global supply chain for essential raw materials, including nucleotides, capping reagents, and lipids, has also faced disruptions, prompting CDMOs to invest in regional manufacturing hubs and vertical integration strategies to ensure uninterrupted production. Additionally, collaborations between CDMOs and biotech firms have strengthened supply chain resilience, enabling rapid response to emerging healthcare challenges. The adoption of digital manufacturing platforms and blockchain-based tracking systems has further improved traceability and compliance, ensuring transparency in the production and distribution of mRNA-based drugs.

What Are the Key Growth Drivers in the mRNA Therapeutics CDMO Market?

The growth in the mRNA therapeutics CDMO market is driven by several factors, including the increasing investment in mRNA drug development, expanding biopharmaceutical pipelines, and the rising need for scalable manufacturing solutions. The success of mRNA-based COVID-19 vaccines has accelerated funding for next-generation mRNA therapies, leading to a surge in clinical trials for infectious diseases, oncology, and metabolic disorders. Pharmaceutical companies are increasingly outsourcing mRNA production to CDMOs to reduce operational costs and accelerate time-to-market. The emergence of next-generation RNA technologies, such as self-amplifying RNA and circular RNA, has further increased demand for specialized CDMO capabilities. Additionally, the growing adoption of modular and single-use bioprocessing systems has enabled CDMOs to offer flexible, cost-effective manufacturing solutions. As governments and biotech firms prioritize pandemic preparedness and personalized medicine, the role of mRNA therapeutics CDMOs is expected to expand, ensuring that innovative mRNA-based treatments reach global markets efficiently and at scale.

SCOPE OF STUDY:

The report analyzes the mRNA Therapeutics Contract Development & Manufacturing Organization market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Infectious Diseases Indication, Metabolic & Genetic Diseases Indication, Cardiovascular & Cerebrovascular Diseases Indication); Application (Viral Vaccines Application, Protein Replacement Therapies Application, Cancer Immunotherapies Application); End-Use (Biotech Companies End-Use, Government & Academic Research Institutes End-Use, Pharmaceutical Companies End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • AGC Biologics
  • Aldevron
  • ARCALIS, Inc.
  • BioNTech SE
  • Catalent, Inc.
  • CordenPharma International
  • Curia Global, Inc.
  • FUJIFILM Diosynth Biotechnologies
  • Laboratorios Farmaceuticos Rovi, S.A.
  • Lonza Group
  • Merck KGaA
  • Moderna, Inc.
  • Rentschler Biopharma SE
  • Samsung Biologics
  • ST Pharm
  • Thermo Fisher Scientific
  • TriLink BioTechnologies
  • Vernal Biosciences
  • WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • mRNA Therapeutics Contract Development & Manufacturing Organization - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surge in mRNA-based Therapeutics Drives Significant Demand for Specialized CDMO Services
    • Increasing Investment in mRNA Vaccine and Therapeutic Development Expands the Addressable Market for CDMOs
    • Growth in Pharmaceutical Outsourcing for mRNA Production Strengthens the Business Case for CDMO Partnerships
    • Technological Advancements in mRNA Manufacturing Processes Propel Growth in CDMO Offerings
    • Rising Need for Scalable and Flexible Manufacturing Solutions Drives the Adoption of CDMO Services in mRNA Production
    • Regulatory Support for mRNA Therapeutics and Vaccines Expands Opportunities for CDMOs in the Market
    • The Emergence of mRNA-based Cancer Therapies Generates Long-term Growth for CDMO Services in Oncology
    • Increasing Complexity of mRNA Synthesis Drives Demand for Advanced Expertise and Technology in CDMO Partnerships
    • Expansion of Global Clinical Trials for mRNA-based Drugs Strengthens Market Opportunities for CDMO Providers
    • The Growing Role of CDMOs in the Production of mRNA Vaccines for Emerging Infectious Diseases Expands Market Reach
    • Increasing Focus on Speed and Efficiency in mRNA Drug Development Accelerates Demand for Specialized CDMO Services
    • The Rise of Personalized Medicine and Targeted Therapies Boosts Demand for Custom CDMO Solutions in mRNA Production
    • Increasing Collaboration Between Biopharma Companies and CDMOs Expands Market Growth Potential for mRNA Therapeutics
    • The Growth of Public and Private Investments in mRNA Technology Strengthens the Financial Case for CDMO Expansion
    • The Need for High-Quality and GMP-compliant Manufacturing Drives Adoption of Leading CDMO Providers for mRNA Production
    • Regulatory Challenges in mRNA Therapeutic Manufacturing Drive Innovation in CDMO Capabilities and Standards
    • The Continued Success of COVID-19 Vaccines Strengthens Long-term Demand for mRNA Therapeutics and CDMO Services
    • The Shift Towards Modular and Automated Manufacturing Solutions Promotes Growth and Efficiency in mRNA CDMOs
    • The Increasing Demand for Global Supply Chain Optimization in mRNA Production Expands CDMO Opportunities
    • Growing Competitive Landscape in mRNA Therapeutics Drives Demand for Specialized and Reliable CDMO Partnerships
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World mRNA Therapeutics Contract Development & Manufacturing Organization Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Infectious Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Infectious Diseases Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Metabolic & Genetic Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Metabolic & Genetic Diseases Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cardiovascular & Cerebrovascular Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Cardiovascular & Cerebrovascular Diseases Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Viral Vaccines Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Viral Vaccines Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Protein Replacement Therapies Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Protein Replacement Therapies Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cancer Immunotherapies Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Cancer Immunotherapies Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Government & Academic Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Government & Academic Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • mRNA Therapeutics Contract Development & Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 22: USA Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • CANADA
    • TABLE 28: Canada Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • JAPAN
    • mRNA Therapeutics Contract Development & Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 34: Japan Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • CHINA
    • mRNA Therapeutics Contract Development & Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 40: China Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • EUROPE
    • mRNA Therapeutics Contract Development & Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 46: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • FRANCE
    • mRNA Therapeutics Contract Development & Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 54: France Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • GERMANY
    • mRNA Therapeutics Contract Development & Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 60: Germany Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • ITALY
    • TABLE 66: Italy Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • UNITED KINGDOM
    • mRNA Therapeutics Contract Development & Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 72: UK Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • ASIA-PACIFIC
    • mRNA Therapeutics Contract Development & Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제